dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Edo Salvador, Angel |
dc.contributor.author | Calvo Barreiro, Laura |
dc.contributor.author | Eixarch Ahufinger, Herena |
dc.contributor.author | Bosch Merino, Assumpció |
dc.contributor.author | Chillon Rodriguez, Miguel |
dc.contributor.author | Espejo Ruiz, Carmen |
dc.date.accessioned | 2022-11-04T08:54:55Z |
dc.date.available | 2022-11-04T08:54:55Z |
dc.date.issued | 2022-09 |
dc.identifier.citation | Edo A, Calvo-Barreiro L, Eixarch H, Bosch A, Chillón M, Espejo C. Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis. Neurotherapeutics. 2022 Sep;19:1617–33. |
dc.identifier.issn | 1525-0024 |
dc.identifier.uri | https://hdl.handle.net/11351/8396 |
dc.description | Receptor soluble; Esclerosi múltiple |
dc.description.sponsorship | Open Access Funding provided by Universitat Autonoma de Barcelona. This project was supported by the Ministerio Ciencia Innovación, retos Sociedad (PI15/0271). A.E was a recipient of a VHIR fellowship. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Neurotherapeutics;19 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Teràpia genètica |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Encefalomielitis - Tractament |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | Encephalomyelitis, Autoimmune, Experimental |
dc.subject.mesh | /therapy |
dc.subject.mesh | Genetic Therapy |
dc.title | Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s13311-022-01279-8 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | encefalomielitis autoinmune experimental |
dc.subject.decs | /terapia |
dc.subject.decs | terapia genética |
dc.relation.publishversion | https://doi.org/10.1007/s13311-022-01279-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Edo A] Institut de Neurociències (INc), Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Calvo-Barreiro L, Eixarch H, Espejo C] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bosch A] Institut de Neurociències (INc), Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Chillón M] Institut de Neurociències (INc), Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain. Vector Production Unit (UPV), Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 35902536 |
dc.identifier.wos | 000794043700261 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |